alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 12

                        ARISTAR, INC. AND SUBSIDIARIES

               COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
                                  (Unaudited)


                                          Year Ended December 31,             
<TABLE>

(Dollars in thousands)          1998       1997      1996       1995      1994
                            --------   --------   -------   --------   --------

Income from operations 
<S>                         <C>        <C>        <C>       <C>        <C>     
before income taxes         $ 87,587   $ 76,031   $99,518   $107,741   $101,311
                            --------   --------   -------   --------   ---------
Fixed charges:
  Interest and debt
  expense on all
  indebtedness               133,211   128,887    120,758   114,917    102,224

Appropriate portion
  of rentals (33%)             3,718      3,565     3,292      3,359     3,020

Total fixed charges          136,929    132,452   124,050    118,276   105,244
                            --------    -------   -------    -------   -------
Earnings available for
  fixed charges             $224,516   $208,483   $223,568  $226,017   $206,555
                            --------   --------   --------  --------   --------
Ratio of earnings to
  fixed charges                 1.64       1.57      1.80       1.91      1.96
                            --------   --------   -------   --------   --------
</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of General Medical Sciences; Initial Review Group Minority Programs Review, Subcommittee B.                    

*Date:*                         July 9-10, 2009.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.                    

*Contact Person:*                         Rebecca H. Johnson, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18C, Bethesda, MD 20892. 301-594-2771.                         *Johnsonrhnigms.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: June 4, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-13757 Filed 6-10-09; 8:45 am]

BILLING CODE 4140-01-M
Exhibit
23.1





Consent
of Independent Registered Public Accounting Firm





We
consent to the incorporation by reference in Registration Statements (Nos.
333-118292, 333-118291, 333-78355, 333-44489, 333-5912 and 333-5910) on Form S-8
of Balchem Corporation and subsidiaries of our reports dated March 17, 2008
relating to our audit of the consolidated financial statements, the financial
statement schedule and internal control over financial reporting, which appear
in this Annual Report on Form 10-K of Balchem Corporation for the year ended
December 31, 2007.





/s/McGladrey
& Pullen, LLP


New York,
New York


March 17,
2008











67
EXHIBIT 32.1

                                  CERTIFICATION

     Certification  Pursuant  to Section 906 of the  Sarbanes-Oxley  Act of 2002
(Subsections (a) and (b) of Section 1350,  Chapter 63 of Title 18, United States
Code)

     Pursuant to section 906 of the  Sarbanes-Oxley Act of 2002 (subsections (a)
and (b) of section 1350,  chapter 63 of title 18,  United States Code),  each of
the undersigned officers of Zoom Technologies, Inc., a Delaware corporation (the
"Company"),  does hereby  certify,  to the best of such officer's  knowledge and
belief, that:

(1)  The Quarterly  Report on Form 10-Q for the quarter ended September 30, 2004
     (the "Form 10-Q") of the Company fully  complies with the  requirements  of
     section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The  information  contained  in  the  Form  10-Q  fairly  presents,  in all
     materials  respects,  the financial  condition and results of operations of
     the Company.



Dated:  November 12, 2004                       /s/ Frank B. Manning
                                            ------------------------------------
                                            Frank B. Manning
                                            Chief Executive Officer

<PAGE>
                                  EXHIBIT 32.2

                                  CERTIFICATION

Certification  Pursuant  to  Section  906 of  the  Sarbanes-Oxley  Act  of  2002
(Subsections (a) and (b) of Section 1350,  Chapter 63 of Title 18, United States
Code)

     Pursuant to section 906 of the  Sarbanes-Oxley Act of 2002 (subsections (a)
and (b) of section 1350,  chapter 63 of title 18,  United States Code),  each of
the undersigned officers of Zoom Technologies, Inc., a Delaware corporation (the
"Company"),  does hereby  certify,  to the best of such officer's  knowledge and
belief, that:

(1)  The Quarterly  Report on Form 10-Q for the quarter ended September 30, 2004
     (the "Form 10-Q") of the Company fully  complies with the  requirements  of
     section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The  information  contained  in  the  Form  10-Q  fairly  presents,  in all
     materials  respects,  the financial  condition and results of operations of
     the Company.

Dated:  November 12, 2004                       /s/ Robert A. Crist
                                            ------------------------------------
                                            Robert A. Crist
                                            Chief Financial Officer
**EXHIBIT 31.1**

**CERTIFICATIONS**

I, John S. Roberts, certify that: 

1. I have reviewed this quarterly report on Form 10-Q of Union Security Insurance Company; 

2. Based on myknowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respectto the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report,fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have: 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designedunder our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is beingprepared; 

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report ourconclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscalquarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of the registrant’s board of directors (or persons performing the equivalent functions): 

(a) All significant deficienciesand material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’sinternal control over financial reporting. 

Date: May 12, 2008
#### RELIABLE MACHINE WORKS v. UNGER.

United States District Court S. D. New York.

Dec. 10, 1955.

James & Franklin, New York City, for plaintiff.

Harry Price, New York City, for defendants.

DAWSON, District Judge.

This is a motion by the defendants which, among other things, seeks an order dismissing the complaint or, in the alternative, an order granting summary judgment upon two grounds set forth in the motion papers. So much of this motion as seeks this relief is denied.

• Defendants, in the alternative, seek an order compelling the plaintiff to separately state and number its cause of action so as to allege in separate causes of action any claims that it may have against the defendants (1) for patent infringement, (2) for breach of the contract, a copy of which is annexed to the complaint, and (3) for violation of a consent judgment entered in this Court, a copy of which is annexed to the complaint.

The complaint is inartistieally drawn. It is not clear whether it seeks damages solely for patent infringement or whether it also seeks relief for alleged violation of the consent judgment and damages for breach of contract. If it seeks *486relief solely for patent infringement, it is difficult to see why the contract and the consent judgment were pleaded and why damages were alleged for violation of the consent judgment and breach of the contract. If, however, the action is one other than for patent infringement, a question might arise as to whether the Court has jurisdiction of a cause of action for breach of the contract, and whether it has jurisdiction of an action against these defendants for violation of the consent judgment which was not against them individually.

So much of the motion as seeks an order directing the plaintiff to serve an amended complaint in which it will separately state and number its causes of action is granted.

So much of the motion as seeks to compel plaintiff to make a more definite statement of allegations in the complaint is denied.

So ordered.
Exhibit 31(d)

CERTIFICATIONS

** 
I, Joseph F. Domino, certify that:  
1.
I have reviewed this annual report on Form 10-K of Entergy Gulf States, Inc.;  
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  
4.
The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:   
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;   
b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;   
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and   
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and  
5.
The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):   
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and   
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

		/s/ Joseph F. Domino		

**
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
     This schedule contains summary financial information extracted from the
Condensed Consolidated Interim Balance Sheet and the Condensed Consolidated
Interim Statement of Operations and is qualified in its entirety by reference to
financial statements.
</LEGEND>
<MULTIPLIER> 1,000,000
<CURRENCY> CANADIAN DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-1999
<EXCHANGE-RATE>                                 1.5080
<CASH>                                              10
<SECURITIES>                                         0
<RECEIVABLES>                                       65
<ALLOWANCES>                                         0
<INVENTORY>                                         71
<CURRENT-ASSETS>                                   146
<PP&E>                                           1,428
<DEPRECIATION>                                     456
<TOTAL-ASSETS>                                   1,298
<CURRENT-LIABILITIES>                              200
<BONDS>                                          1,088
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                         16
<COMMON>                                           641
<OTHER-SE>                                         777
<TOTAL-LIABILITY-AND-EQUITY>                     1,298
<SALES>                                            145
<TOTAL-REVENUES>                                   163
<CGS>                                              100
<TOTAL-COSTS>                                      124
<OTHER-EXPENSES>                                     1
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  28
<INCOME-PRETAX>                                     (9)
<INCOME-TAX>                                         1
<INCOME-CONTINUING>                                 (9)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        (9)
<EPS-PRIMARY>                                     (0.1)
<EPS-DILUTED>                                     (0.1)
        

</TABLE>
Exhibit 21
Subsidiaries of Arvin Industries, Inc.

Set forth below are the names of certain subsidiaries, at least 50% owned,
directly or indirectly, of the Company included in the consolidated financial
statements of the Company and its subsidiaries in the Company's Annual Report on
Form 10-K for the year ended January 3, 1999. Certain subsidiaries, which when
considered in the aggregate would not constitute a significant subsidiary, are
omitted from the list below. <TABLE> <CAPTION>



                                                                    State or Other Jurisdiction of
Company Name                                                        Incorporation
------------                                                        -------------
<S>                                                                 <C>
Maremont Corporation                                                Delaware
Maremont Exhaust Products, Inc.                                     Delaware
Gabriel Europe, Inc.                                                Delaware
Gabriel Ride Control Products, Inc.                                 Delaware
Arvin International Holdings, Inc.                                  Delaware
Arvin-Kayaba, LLC                                                   Indiana
Arvin Technologies, Inc.                                            Michigan
AVM, Inc.                                                           South Carolina
Arvin Automotive of Canada                                          Canada
Arvin Ride Control Products, Inc.                                   Canada
Arvin Finance Company of Canada                                     Canada
Arvin Canada Holding, Ltd.                                          Canada
Arvin-Exhaust B.V.                                                  The Netherlands
Arvin International Holland B.V.                                    The Netherlands
Timax Exhaust Systems Holding B.V.                                  The Netherlands
Arvin-Exhaust S.A.                                                  Spain
Arvin France S.A.                                                   France
Arvin Exhaust S.A.                                                  France
Arvin Exhaust GmbH                                                  Germany
Zeuna Starker GmbH & Co KG                                          Germany
Arvin International U.K., Ltd.                                      United Kingdom
Arvin Replacement Products, Ltd.                                    United Kingdom


</TABLE>

                                       77
#### Esther Johnson, et al., plaintiff v John Cauthen, Appellant.

[824 NYS2d 341]

In an action to recover damages for personal injuries, the defendant appeals, as limited by his brief, from so much of an order of the Supreme Court, Kings County (Lewis, J.), dated July 22, 2005, as denied that branch of his motion which was for summary judgment dismissing the complaint insofar as asserted by the plaintiff Esther Johnson on the ground that she did not sustain a serious injury within the meaning of "Insurance Law § 5102 (d).

Ordered that the order is affirmed insofar as appealed from, with costs.

The defendant failed to carry his burden of establishing, prima facie, that the plaintiff Esther Johnson did not sustain a *966serious injury within the meaning of Insurance Law § 5102 (d) as a result of the subject accident *(see Toure v Avis Rent A Car Sys.,*98 NY2d 345 [2002]; *Gaddy v Eyler,*79 NY2d 955 [1992]). Although the defendant’s examining neurologist asserted, in an affirmed medical report, that Johnson had a “full” range of motion in the cervical and lumbar regions of her spine and the defendant’s examining orthopedist asserted, in an affirmed medical report, that Johnson had “full” range of motion in the cervical region of her spine, the defendant’s proof was insufficient because neither physician set forth the basis for those conclusions *(see Nembhard v Delatorre,*16 AD3d 390 [2005]; *Black v Robinson,*305 AD2d 438 [2003]). Since the defendant failed to establish his prima facie entitlement to judgment as a matter of law, it is unnecessary to consider whether Johnson’s opposition papers were sufficient to raise a triable issue of fact *(see Nembhard v Delatorre, supra; Coscia v 938 Trading Corp.,*283 AD2d 538 [2001]). Schmidt, J.E, Ritter, Mastro, Fisher and Dillon, JJ., concur.
*Monday, February 24, 1997*

MISCELLANEOUS DISMISSALS

97-377.

#### State ex rel. Montgomery v. Marcelain.

In Mandamus and Prohibition. This cause originated in this court on the filing of a complaint for writs of mandamus and prohibition and was considered in a manner prescribed by law. Upon consideration thereof,

IT IS ORDERED by the court that this cause be, and hereby is, dismissed, effective February 21, 1997.

Douglas, J., would defer consideration until the response of respondents is received.